OSTEOPOROSIS.

Slides:



Advertisements
Similar presentations
OSTEOPOROSIS An overview of the condition and its treatment
Advertisements

May  Df: A progressive systemic skeletal disorder characterised by a low bone mass and micro- architectural deterioration of bone.  T score of.
A progressive bone disease characterized by decrease bone mass decreased bone density increased fracture risk Dr Gaurav Rathore MS Ortho, MCh Ortho, FRCS.
Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.
WHO Osteoporosis Definition (1996)
Osteoporosis By Lacie and Janay.
Osteoporosis Created by: Tricia Fleming, University of Kansas Dietetic Intern Tammy Beason, MS, RD, Nutrition Education Specialist, Family Nutrition Education.
King Abdul Aziz University Faculty Of Pharmacy
Dr santosh kumar Assistant professor Medical unit 2.
Osteoporosis Lucy Cowdrey 4 th November What is it?
Bones, Calcium, and Osteoporosis. Bone Bone is living, constantly remodeled Reservoir of Calcium – Calcium levels of blood take precedence over bone levels.
Osteoporosis Dr. Lauren Phillips Sugar Land Women’s Health.
Osteoporosis UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley.
Bone Mineral Density Testing March 29, Introduction Osteoporosis is a systemic skeletal disorder characterized by decreased bone mass and deterioration.
Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.
Osteoporosis Let’s Work Together to Get Bone Healthy!
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
OSTEOPOROSIS 06/25/12 José L. González, PGY3. Definition  Reduction in bone strength  increase risk of fx  T-score: < -2.5 SDs  T-score: 30 yo, matched.
Beyond 5 years Francis F. Lopez, MD Medical Oncology.
Osteoporosis and Fractures Are Common, and Becoming More So
Quiz of the week. 23 years old male patent who presented with sudden onset of sever back pain and his MRI of spine shows a fracture. How do you approach.
Osteoporosis Awareness and Prevention Lunch n Learn Series May 2007.
Osteoporosis Dr. Faik Altıntaş Yeditepe Üniversitesi Tıp Fakültesi
By Siraya Kitiyodom ปัญหาที่เกี่ยวกับสุขภาพ ที่พบบ่อยในสตรีวัยทอง และวิธีการดูแล (Part II)
Vietnam Osteoporosis Workshop, HCM Cty 2006 OSTEOPOROSIS IN MEN Tuan Van Nguyen and Nguyen Dinh Nguyen Garvan Institute of Medical Research Sydney, Australia.
A Look at Osteoporosis Screening Guidelines Cynthia Phelan PGY
What is the Bone?. Connective tissue  Organic matrix (cells & proteins)  Inorganic elements (calcium hydroxyapatite)
R R R R C C OSTEOPOROSIS R heumatology R esearch C enter INTERNAL MEDICINE CONGRESS 1382.
OSTEOPOROSIS. It is the thinning of the bony tissue and the loss of the density in the bones with the time.
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
Alimohammad Fatemi Assistant Professor of Rheumatology 1.
Vitamin D, Rickets and Osteoporosis
Osteoporosis By Dr. Khattab Omar Prof. & Head of Obstetrics and Gynaecology Department Faculty of Medicine, Al-Azhar University, Damietta.
COMMON LIFESTYLE DISEASES: OSTEOPOROSIS
Bones Part 4 DR. T Jim, Tyler and Matt.
Definition Definition Osteoporosis:A condition of skeletal fragility characterized by reduced bone mass and microarchitectural deterioration of.
Osteoporosis In Thalassemia Dr Tarek Jawad INT 555.
Welcome To Our Presentation
OSTEOPOROSIS. Characteristics of osteoporosis include a reduction of bone density and a change in bone structure, both of which increase susceptibility.
Osteopenia and Osteoporosis Bradley K. Harrison, MD.
NICE, FRAX & NOGG VTS meeting Jonathan Day 7 th April 2010.
Chapter ?? 23 Osteoporosis Nichols and Pavlovic C H A P T E R.
OSTEOPOROSIS Dr Annie Cooper Consultant Rheumatologist Royal Hampshire County Hospital Winchester.
Chapter 48 Evaluation of Postmenopausal Osteoporosis © American Society for Bone and Mineral Research Contributed by Susan Greenspan and Marjorie Luckey.
Osteoporosis Risk Factors... Are You at Risk? Osteoporosis is a disease that leads to decreased bone density and leaves the bones weak and easily fractured.
 Osteoporosis means "porous bones," causes bones to become weak and brittle – so brittle that even mild stresses like bending over, lifting a vacuum.
Calcium, Bone Health & Osteoporosis - Introduction University of Georgia Cooperative Extension Service.
GERIATRICS Dr. Meg-angela Christi Amores. Musculoskeletal Disorders in the Elderly  Osteoarthritis  Rheumatoid Arthritis  Gout (Gouty arthritis) 
Osteoporosis Vinod Kurup, MD December 22nd, 2006 CC-BY-SA.
Osteoporosis. Definitions: - - Osteoblasts: Fibroblasts essential for bone formation and mineralization of bone matrix - - Osteoclasts: Cells that break.
Osteoporosis
Osteoporosis.
Osteoporosis هشاشة العظام Dr.Fakhir Yousif.
Drugs Affecting Calcium Levels and Bone Mineralization
Patient 65 years old retired teacher with severe back pain
Salman Bin AbdulAziz University
Osteoporosis and Vitamin D deficiency
Post Menopausal Osteoporosis
BONE PROBLEMS.
بنـام خـدا.
Osteoporosis Definition
OSTEOPOROSIS. OSTEOPOROSIS Osteoporosis Osteoporosis affects both men and women. Its prevalence increases with age, and it is particularly common in.
Chapter Drugs used for the treatment of osteoporosis
Lecture 6 Rheumatologic Disorders Osteoporosis
(Relates to Chapter 64, “Focous on osteoperosis ,” in the textbook)
Reporting the Results of DXA Scan
Osteoporosis: Definition
Consultant Rheumatologist Imperial College Healthcare
Presentation transcript:

OSTEOPOROSIS

GOALS: RECOGNIZE THE IMPORTANCE OF OSTEOPOROSIS. APPLY GENERAL DIAGNOSTIC AND TREATMENT GUIDELINES FOR OP. OBJECTIVES: BY THE END OF THIS PRESENTATION, THE STUDENT SHOULD BE ABLE TO: -DEFINE OP -KNOW THE CAUSES AND RISK FACTORS OF OP. -WHEN TO SCREEN FOR OP. -RECOGNIZE GENERAL PRINCIPLES OF MANAGEMENT. -TALK ABOUT PREVENTIVE MEASURES OF OP.

Description: Decreased bone strength (density and/or quality) leading to increased risk for fragility fracture. Bones of hip, spine and wrist most commonly affected.

IMPORTANCE - Osteoporosis is a major public health problem, which results in substantial morbidity, mortality and high costs. -Osteoporosis is an extremely serious disease and is not part of the natural aging process.

- Osteoporosis is underdiagnosed, undertreated and a neglected disease. --The loss occur primarily in trabecular bone and is therefore most noticeable in the vertebrae and distal radius

Pathogenesis: increased bone resorption and/or decreased bone formation (defective mineralization of osteoid) maximum bone density reached at age 30-35 years (95% reached by mid-teens) 10% decrease in bone mass doubles risk of fracture.   

Normal BMD is within 1 SD of young adult mean (T-score at -1 and above) Osteopenia is BMD within -1 SD and - 2.5 SD below young adult mean (T-score between -1 and -2.5) osteoporosis is BMD ≤ -2.5 SD below young adult mean (T-score at or below -2.5)

Z-scores represent the number of SDs from normal mean value for age- and sex-matched control subjects. clinical diagnosis of osteoporosis is fragility fracture regardless of T-score.

Types of Osteoporosis: (A) Type I osteoporosis is postmenopausal and usually presents with type A fractures. (e.g fractured of trabecular bone which is found in vertebrae and the wrist).

(B) Type II osteoporosis is senile osteoporosis that involves loss of cortical and trabecular bone and presents with type B fractures (hip). Type II occurs primarily in men and women over the age of 75.

Causes of Osteoporosis (A) Idiopathic age-related osteoporosis (most common): (1) Juvenile The mean age of onset 7 yr. no sex difference. long bone fractures, pain in the back and difficulty walking, often it resolves itself after puberty (2) Young adults unknown cause, the bones become fragile and break, just as they do in people with Type I and Type II osteoporosis.

(3) Postmenopausal (type I) only women, loss of estrogen that occurs after menopause, affect the trabecular (porous, spongy) bone mainly in the vertebrae and wrist (4) Senile (type II) both men and women, age related changes , affect cortical and trabecular …suffer from hip, wrist and spine fractures .

Secondary Osteopoosis (B) Osteoporosis secondary to disease states: 1. Metabolic conditions e.g calc. deficiency, vit. D deficiency, malnutrition, Idiopathic hypercalciuria, renal tubular acidosis, scurvy. 2. Endocrine conditions e.g Thyrotoxicosis, Cushing, hypogonadism, Prolactinoma, Hyperparathyroidism, Hypoamenorrheic female runners. 3. Renal disease.

4. Gastrointestinal disease. Eg. IBD, interfere with absorption of calcium 5. Hereditary connective tissue diseases e.g marfan syndrome, homocystinuria. 6.Bone marrow infiltration e.g Multiple myeloma, lymphoma, leukemia.

7. Drugs e.g Phenytoin, Phenobarbital, Thyroid hormones, Corticosteroid(7.5mg pred for >3 months), chronic heparin/warfarin therapy , lasix , lithium, . 8. Life style e.g Nutnition, alcohol, smoking, inactivity, immobilization, excessive caffeine, excess phosphate intake (soft drinks, red meat). 9. Miscellaneous e.g Rh. arthritis , DM, Hypetension.

Organs involved: Trabecular bone more commonly affected than compact bone Spine (vertebral column), pelvis, hip (femoral neck), distal radius, metacarpals

Who is most affected: women (especially postmenopausal), elderly older white women have higher risk of incident nonspinal fractures than older black women

osteoporosis can develop in men main risk factors for osteoporosis smoking alcohol excess body mass index < 21 kg/m2 family history of osteoporosis

factors associated with osteoporotic fractures Age body mass index (BMI) smoking status recorded alcohol use rheumatoid arthritis cardiovascular disease

type 2 diabetes asthma use of tricyclic antidepressants use of corticosteroids history of falls liver disease

Complications: osteoporosis associated with significantly increased risk for clinical fractures at 1 year. low bone mineral density (BMD) associated with risk of high-trauma fractures as well as low-trauma fractures

Clinical manifestations of Osteoporosis: Osteoporosis is usually asymptomatic until fracture occurs. May present as backache of varying degrees of severity Spontaneous fracture Collapse of vertebrae Loss of height is common -

There is greater loss of trabecular bone than compact bone which cause crush fractures of vertebrae, fractures of the neck of femur and fractures of the distal end of the radius. - The rate of bone formation is often normal whereas the rate of bone resorption is increased. Bone is normally mineralized

Physical Exam: Signs are few, may decreasing height or a dorsal kyphosis . p.t should be assessed for localized pain, muscle spasm, Neurologic deficit, loss of strength and range of motion in the affected area. Fractures most commonly occur in the vertebral bodies, wrist, humerus, hip. rib and pelvis (in that order).

 Diagnosis 1-Based on bone densometry (DEXA scan) with the use of T or z score. 2- Clinical diagnosis if fragility fracture, regardless of T/Z-score.

T and Z scores T-score is bone density expressed as number of standard deviations (SD) above or below mean bone mineral density (BMD) value for a normal young adult, measured by dual-energy x-ray absorptiometry(DEXA).

T score ≥ -1 is normal. T-score between -1 and -2.5 is osteopenia T-score ≤ -2.5 is osteoporosis

In premenopausal women, men < 50 years old, and children, use z-score instead of T-score . z-score is bone density expressed as number of SDs from normal mean value for age, sex, and ethnicity/race z-score > -2 is normal z-score ≤ -2 is OP

Laboratory Findings: Do Serum calcium, phosphate and PTH (they are normal). The alkaline phosphatase is usually normal but may be slightly elevated esp. following a fracture. TSH and Vit. D for deficiency may be required. other tests is guided by clinical suspicion.

When to do bone densometry: 1. Estrogen-deficient women at clinical risk. 2. An individual with vertebral abnormalities on plain film. 3. More than 3 months of steroid Rx or pt.

4. Primary hyperparathyroidism. 5. Monitoring of drug therapy. 6 4. Primary hyperparathyroidism. 5. Monitoring of drug therapy. 6. Women who have multiple risk factors. 8. Pt. with strong F.H of osteoporosis. 9. All women age>65

1-clacium. rich diet esp. in childhood. Prevention: Exercise Calcium and vitamin D Bisphosphonates Vitamin K Estrogen Raloxifene (Evista 1-clacium. rich diet esp. in childhood. daily calcium intake of at least 1000mg , adolescents may need 1200mg and postmenopausal women may need 1500mg daily. Women of any age unable to meet minimal calc. needs through diet should be advised to use supplemental calcium. Elderly should be advised to take >800 units of Vit. D daily. Milk, cheese and yogurt are rich in calcium. 2- No Smoking

Screening: women men any adult with age ≥ 65 years Before that if women with clinical risk factors men age ≥ 70 years age 50-69 years with clinical risk factors any adult with fracture after age 50 years condition (such as rheumatoid arthritis) associated with low bone mass or bone loss use of medication (such as glucocorticoids) associated with low bone mass or bone loss

Treatment of Osteoporosis 1 Treatment of Osteoporosis 1. If history of fragility fractures treatment should be started . 2. Bisphosphonates: alendronate and risedronate, the selective estrogen-receptor modulator raloxifene, the anabolic agent PTH and strontium ranelate are known to reduce vertebral fractures.

4. HRT is not recommended in women for fracture risk reduction alone. 5. The efficacy of calcitonin, fluoride, anabolic steroids and active vitamin D metabolites is questionable. individual’s absolute risk of fracture is the single most important consideration .

Who should be treated. (a) T score of <-2. 5(OP) Who should be treated ? (a) T score of <-2.5(OP). (B) Previous fragility fracture: the risk of further fractures increases threefold to fivefold. (C)Osteopenia with: history of fracture or family history of osteoprosis. (D) Risk factors for bone loss e.g hyperparathyroidism, corticosteroid therapy, immobilization, chronic illness.

Which drug should be used? a) alendronate, risedronate , raloxifene or PTH are used to reduce risk of vertebral facture b) biphosphonates only for non vertebral fractures. For the treatment of postmenopausal symptoms use HRT . to reduce breast cancer risk use raloxifene.

How long should treatment continue? It remains unclear whether anti-fracture efficacy is sustained beyond 3-5 years. Stopping treatment is followed by increased remodeling, bone loss and further structural damage. Bone loss is likely to recur sooner after cessation of HRT or raloxifene than biphosphonates.

In conclussion If BMD is > -1 SD do not treat If BMD is –1 to –2.5 SD treat if fracture is present If BMD is < -2.5 SD treat whether or not a fracture is present